Pentostatin, cyclophosphamide and rituximab is a safe and effective treatment in patients with Waldenström’s macroglobulinemia

Abstract Waldenström’s macroglobulinemia (WM) is an indolent lym phomaand is responsive to therapy regimens containing alkylating agents, purine analogs and rituximab if treatment becomes necessary. We initiated a multicenter phase II trial to determine the safety and efficacy of a regimen containing pentostatin, cyclophosphamide and rituximab (PER) in patients with WM. Between May 2005 and December 2010, 25 patients with WM were included in the study. Twenty-one patients received PER as first-line therapy. In these patients, 2-year progression-free survival was 83.6% and 2-year overall survival was 100%. Thirteen patients (52%) received R maintenance therapy. In these patients, the 2-year progression-free survival was 91.67% and 2-year overall survival was 100%. We have provided evidence that PER is a safe and effective regimen for WM. Although R maintenance therapy after PER seemed to induce a better long-term outcome, this study was not powered to address this issue.

[1]  R. Advani,et al.  A Prospective Multicenter Study Of The Bruton’s Tyrosine Kinase Inhibitor Ibrutinib In Patients With Relapsed Or Refractory Waldenstrom’s Macroglobulinemia , 2013 .

[2]  M. Tatsumi,et al.  Multicenter phase II study of bendamustine plus rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  M. Baer,et al.  Rituximab maintenance therapy until progression after rituximab and chemotherapy induction in patients with follicular lymphoma. , 2013, Clinical lymphoma, myeloma & leukemia.

[4]  E. Kimby,et al.  Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop , 2013, British journal of haematology.

[5]  Tuan S. Nguyen,et al.  A Multicenter Phase II Study of Single-Agent Enzastaurin in Previously Treated Waldenström Macroglobulinemia , 2012, Clinical Cancer Research.

[6]  H. Döhner,et al.  Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  M. Grever,et al.  Pentostatin and rituximab therapy for previously untreated patients with B‐cell chronic lymphocytic leukemia , 2010, Cancer.

[8]  P. Richardson,et al.  Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  P. Richardson,et al.  Clinical and Translational Studies of a Phase II Trial of the Novel Oral Akt Inhibitor Perifosine in Relapsed or Relapsed/Refractory Waldenström's Macroglobulinemia , 2010, Clinical Cancer Research.

[10]  D. Esseltine,et al.  Primary therapy of Waldenström macroglobulinemia with bortezomib, dexamethasone, and rituximab: WMCTG clinical trial 05-180. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  J. Crowley,et al.  International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.

[13]  E. Eisenhauer,et al.  Bortezomib in relapsed or refractory Waldenström's macroglobulinemia. , 2009, Clinical lymphoma & myeloma.

[14]  K. Anderson,et al.  Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia , 2009, Clinical Cancer Research.

[15]  E. Kimby,et al.  Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia. , 2008, Blood.

[16]  W. Klapper,et al.  The addition of rituximab to front-line therapy with CHOP (R-CHOP) results in a higher response rate and longer time to treatment failure in patients with lymphoplasmacytic lymphoma: results of a randomized trial of the German Low-Grade Lymphoma Study Group (GLSG) , 2009, Leukemia.

[17]  Lisa L. Smith,et al.  Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. , 2006, Blood.

[18]  C. Tam,et al.  Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non‐hodgkin lymphoma , 2006, Cancer.

[19]  A. Zelenetz,et al.  Pentostatin, cyclophosphamide, and rituximab is an active, well-tolerated regimen for patients with previously treated chronic lymphocytic leukemia. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  A. Ho,et al.  Pentostatin and purine analogs for indolent lymphoid malignancies. , 2006, Future oncology.

[21]  J. Tamburini,et al.  Fludarabine plus cyclophosphamide in Waldenström's macroglobulinemia: results in 49 patients , 2005, Leukemia.

[22]  A. Ho,et al.  Pentostatin/cyclophosphamide with or without rituximab: an effective regimen for patients with Waldenstrom's macroglobulinemia/lymphoplasmacytic lymphoma. , 2005, Clinical lymphoma & myeloma.

[23]  E. Kimby,et al.  Extended rituximab therapy in Waldenström's macroglobulinemia. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  M. Rue,et al.  Multicenter Phase 2 Trial of Rituximab for Waldenström Macroglobulinemia (WM): An Eastern Cooperative Oncology Group Study (E3A98) , 2004, Leukemia & lymphoma.

[25]  T. Lister,et al.  Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.

[26]  M. Dimopoulos,et al.  Treatment of Waldenström's macroglobulinemia with rituximab. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  J. Byrd,et al.  CD20-Directed Antibody-Mediated Immunotherapy Induces Responses and Facilitates Hematologic Recovery in Patients With Waldenstrom’s Macroglobulinemia , 2001, Journal of immunotherapy.

[28]  E. Coche,et al.  Phase I/II study of 2-chloro-2′-deoxyadenosine with cyclophosphamide in patients with pretreated B cell chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma , 2000, Leukemia.

[29]  B. Coiffier,et al.  European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  D. Betticher,et al.  Cladribine with cyclophosphamide and prednisone in the management of low-grade lymphoproliferative malignancies , 1999, British Journal of Cancer.